Adverts

Open Access Articles- Top Results for Mesuximide

Mesuximide

</th></tr></th></tr>
Mesuximide
250px
Systematic (IUPAC) name
(RS)-1,3-dimethyl-3-phenyl-pyrrolidine-2,5-dione
Clinical data
AHFS/Drugs.com Consumer Drug Information
MedlinePlus a682028
  • US: C (Risk not ruled out)
Oral
Pharmacokinetic data
Metabolism Hepatic (demethylation and glucuronidation)
Half-life 1.4–2.6 hours (mesuximide)
28–38 hours (active metabolite)
Excretion Renal
Identifiers
77-41-8 7pxY
N03AD03
PubChem CID 6476
DrugBank DB05246 7pxN
ChemSpider 6231 7pxY
UNII 0G76K8X6C0 7pxY
KEGG D00404 7pxY
ChEMBL CHEMBL697 7pxY
Chemical data
Formula C12H13NO2
203.237 g/mol
 14pxN (what is this?)  (verify)

Mesuximide (or methsuximide, methosuximide) is a succinimide anticonvulsant medication. It is sold as a racemate by Pfizer under the tradenames Petinutin (Switzerland)[1] and Celontin (United States).[2] The therapeutic efficacy of methosuximide is largely due to its pharmacologically active metabolite, N-desmethylmethosuximide, which has a longer half-life and attains much higher plasma levels than its parent.[3]

References

  1. Pfizer AG (2005). "Petinutin (Mésuximide)". Official Pfizer AG Website (in French). Retrieved August 21, 2006. [dead link]
  2. Pfizer Inc. (2008). "Celontin (methsuximide capsules, USP)". Official Pfizer Inc. Website. Retrieved November 21, 2014. 
  3. Porter RJ, Penry JK, Lacy JR, Newmark ME, Kupferberg HJ. Plasma concentrations of phensuximide, methosuximide, and their metabolites in relation to clinical efficacy. Neurology 29: 1509-1513, 1979.


Lua error in package.lua at line 80: module 'Module:Buffer' not found.